Craig Wierum, MD
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1609867233
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,100,781 of the $1,312,919 with a category attached, or 83.8%. Lilly USA, LLC accounts for 60.9% of it on its own, with 38 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,247 payments — averaging $584.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$799K
- Novo Nordisk$432K
- Boehringer Ingelheim$63K
- Corcept Therapeutics$4K
- Mannkind Corporation$2K
- AbbVie$2K
- plus $10K from 33 others
Across 309 payments — averaging $1189.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$368K
What the payments were for
- Consulting fees$34,2263%
- Speaking & faculty fees$1,100,78184%
- Travel & lodging$141,92211%
- Food & beverage$35,6603%
- Education$3300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 1,133 | $798,937 |
| Novo Nordisk | 443 | $432,240 |
| Boehringer Ingelheim | 133 | $63,250 |
| Corcept Therapeutics | 15 | $4,248 |
| Mannkind Corporation | 150 | $2,015 |
| AbbVie | 12 | $1,876 |
| Amgen | 63 | $1,863 |
| Abbott | 104 | $1,549 |
| Insulet Corporation | 25 | $871 |
| Cequr Corporation | 3 | $705 |
| Medtronic(2 entities) | 22 | $649 |
| Tandem Diabetes Care, Inc. | 12 | $553 |
| BETA Bionics, Inc. | 20 | $517 |
| Xeris Pharmaceuticals, Inc. | 23 | $490 |
| Sanofi-aventis U.S. LLC | 14 | $487 |
| AstraZeneca | 9 | $473 |
| Dexcom, Inc. | 10 | $320 |
| Ascendis Pharma Endocrinology Inc | 11 | $211 |
| Amneal Pharmaceuticals LLC | 11 | $211 |
| Novartis | 2 | $179 |
| Valeritas, Inc. | 2 | $137 |
| Bayer | 1 | $130 |
| Companion Medical, Inc. | 1 | $125 |
| Radius Health, Inc. | 1 | $118 |
| Zealand Pharma US, Inc. | 1 | $117 |
| Eisai Inc. | 1 | $109 |
| IBSA Pharma Inc. | 5 | $97 |
| Ascensia Diabetes Care US Inc. | 3 | $70 |
| Amphastar Pharmaceuticals, Inc. | 3 | $65 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $58 |
| Sequel Med Tech, LLC | 2 | $57 |
| Nevro Corp. | 2 | $37 |
| Bigfoot Biomedical Inc | 1 | $26 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Senseonics, Incorporated | 1 | $24 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| GSK | 1 | $21 |
| Sanofi | 1 | $20 |
| Halozyme Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$324,015
- TRULICITY$269,877
- Ozempic$209,139
- RYBELSUS$173,827
- MOUNJARO$122,169
- Xultophy 100/3.6$7,890
- Tresiba$5,842
- Korlym$4,148
- CeQur Simplicity$705
- EVENITY$690
- iLet Bionic Pancreas$434
- MINIMED 780G$255
- FARXIGA$245
- Omnipod$230
- Repatha$227
- t-slim insulin pump$224
- TZIELD$148
- DEXCOM G7 GSS (161)$146
- iLet Insulin Infusion Kit Inset$145
- iLet Insulin Infusion Kit Contact Detach$145
How this compares
$1,312,919 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $85,311 |
| MounjaroTirzepatide | 75 | $73,801 |
| TrulicityDulaglutide | 46 | $66,042 |
| ForteoTeriparatide | 13 | $54,653 |
| Repatha SureclickEvolocumab | 72 | $47,390 |
| JardianceEmpagliflozin | 44 | $40,816 |
| SynthroidLevothyroxine Sodium | 308 | $28,143 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $15,071 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $14,488 |
| Levothyroxine Sodium | 533 | $6,780 |
| LevoxylLevothyroxine Sodium | 49 | $3,202 |
| Calcitriol | 73 | $2,731 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $2,727 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 14 | $2,511 |
| Eplerenone | 14 | $2,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo | $798,937 | $194,496134 claims |
| Novo NordiskOzempic | $432,240 | $85,31162 claims |
| Boehringer IngelheimJardiance | $63,250 | $40,81644 claims |
| AbbVieSynthroid | $1,876 | $28,143308 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $211 | $6,780533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Nashville
- Terri JerkinsNashville$567K
- Michael CarlsonNashville$381K
- Kathryn DahirNashville$225K
- Rodney SnowNashville$181K
- Annis MarneyNashville$26K
- Emily NeelyNashville$21K
- Amanda DanielNashville$20K
- Juliana MatthewsNashville$15K
- Christopher BowmanNashville$14K
- Cheryl FasslerNashville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.